All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX-914
Therapeutic Area: Immunology Product Name: ADX-914
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed Advisors
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 29, 2020
Details:
Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company’s groundbreaking tissue-targeted complement regulation platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ustekinumab
Therapeutic Area: Immunology Product Name: NeuLara
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
All pre-specified criteria showed the clinical pharmacokinetic (PK) similarity of NeuLara, compared to US- and EUsourced Stelara®. NeuLara is being developed as a biosimilar of ustekinumab, an antibody targeting interleukin-12 and -23, approved under the brand name Stelara®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: TFFTAC-LAC
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Company completes dosing of three cohorts with Tacrolimus Inhalation Powder for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASLAN003
Therapeutic Area: Immunology Product Name: ASLAN003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cetirizine HCl
Therapeutic Area: Immunology Product Name: Ceteric Allergy Gummy
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
SGC scientists have developed a suite of technologies that enable the incorporation of various drug compounds into a novel gummy matrix, thus solving drug solubility, stability, and taste issues.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDX-0159
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
First patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria. CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor and inhibits its activity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FR104
Therapeutic Area: Immunology Product Name: FR104
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: AbGn-168H
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The trial is a multi-dose study of Neihulizumab in SR-aGVHD and follows its successful Phase 1a single-dose study which demonstrated a 77% response rate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,890.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 28, 2020
Details:
This candidate is the eighth GPCR-targeted drug candidate to enter clinical trials originating from Sosei Heptares’ StaR® technology and structure-based drug design (SBDD) platform.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
